UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 162 filers reported holding UNIQURE NV in Q3 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,567,440 | -47.7% | 382,629 | -10.7% | 0.02% | -52.4% |
| Q2 2023 | $4,910,046 | +6.5% | 428,451 | +87.1% | 0.04% | -4.5% |
| Q1 2023 | $4,611,838 | +267.5% | 228,989 | +240.1% | 0.04% | +266.7% |
| Q2 2022 | $1,255,000 | +30.6% | 67,332 | +26.6% | 0.01% | +33.3% |
| Q1 2022 | $961,000 | -14.3% | 53,201 | -1.6% | 0.01% | -10.0% |
| Q4 2021 | $1,121,000 | -16.4% | 54,071 | +29.1% | 0.01% | -28.6% |
| Q3 2021 | $1,341,000 | -43.8% | 41,889 | -40.8% | 0.01% | -51.7% |
| Q1 2021 | $2,385,000 | +74.6% | 70,788 | +87.3% | 0.03% | +61.1% |
| Q4 2020 | $1,366,000 | +105.7% | 37,804 | +109.7% | 0.02% | +38.5% |
| Q3 2020 | $664,000 | -37.1% | 18,029 | -23.0% | 0.01% | -7.1% |
| Q2 2020 | $1,056,000 | -52.1% | 23,400 | -24.0% | 0.01% | -74.1% |
| Q4 2019 | $2,206,000 | +281.7% | 30,779 | +315.9% | 0.05% | +170.0% |
| Q2 2019 | $578,000 | – | 7,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |